SEC Filing Summary: BioSig Technologies, Inc. (Form 8-K)
Business Context and Reporting Period
This Current Report on Form 8-K was filed by BioSig Technologies, Inc. (not Streamex Corp.) on November 13, 2017, covering events occurring on November 6, 2017. The registrant is an emerging growth company incorporated in Delaware with principal executive offices in Minneapolis, Minnesota.
Key Financial Metrics and Transaction Details
The filing reports the consummation of the tenth closing under a Unit Purchase Agreement dated April 6, 2017. Key transaction metrics include:
- Capital Raised: $620,002 in aggregate consideration.
- Securities Issued: 413,336 Units.
- Unit Composition: Each Unit consists of one share of Common Stock and a warrant to purchase 0.5 shares of Common Stock.
- Pricing: Units were sold at $1.50 per Unit; Warrants are exercisable at $1.50 per share.
- Investor Type: Sales were made to accredited investors.
The filing does not provide data on revenue, profit, cash flow, operating margins, debt levels, or general liquidity positions outside of this specific capital raise.
Material Changes and Historical Context
This transaction represents the tenth closing under the Purchase Agreement. The filing details nine prior closings between April 6, 2017, and October 11, 2017, which collectively raised approximately $3,975,398 (sum of reported prior closings). The November 6, 2017 closing adds $620,002 to the total capital raised under this agreement.
Guidance, Risks, and Unusual Items
Regulatory Status: The securities were not registered under the Securities Act of 1933 and were offered in reliance on exemptions under Section 4(a)(2) and Regulation D (Rule 506).
Registration Rights: Investors in this closing became parties to a Registration Rights Agreement dated April 6, 2017.
Outlook: The filing contains no forward-looking guidance, management commentary on operations, or discussion of risks beyond the standard disclosure of unregistered securities sales.
Investor Verification Checklist
- Verify the total aggregate capital raised under the Unit Purchase Agreement by summing all ten closings.
- Confirm the dilution impact of the 413,336 new shares and the associated warrants on existing shareholders.
- Review the Registration Rights Agreement to understand the timeline and conditions for registering these shares for public sale.
- Check subsequent filings for the company's use of the $620,002 proceeds and overall cash runway.
- Confirm the company's current status as an emerging growth company and any related accounting election impacts.